INTERVIEWS

Jude Bond, CEO of Cannaphyll™ Hemp-Infused Topicals, discusses Cannaphyll’s patent-pending  blend of organic phylloceuticals that improves endocannabinoid uptake and delivery. Targeted to active-lifestyle boomers, fitness-enthusiast Gen-Xers, mobility-challenged seniors, high-performance athletes, and chronic pain sufferers, Cannaphyll™ provides more than 1,000mg premium Hemp Extract per 1 ounce, making it more potent than virtually all other OTC hemp-infused topical creams.

Dr. Joe Powers, Chief Strategy Officer at AppliedVR, discusses the collaboration between AppliedVR and the National Cancer Institute, part of the National Institute of Health, to evaluate virtual reality (VR) therapeutics as a solution to help cancer patients suffering from stress and anxiety. 

Ariel talks about her journey of finally receiving a diagnosis of acute hepatic porphyria (AHP), a rare disease characterized by potentially life-threatening pain attacks.  She is now able to manage her disease. She also discusses her experience being treated with Alnylam Pharmaceutical‘s GIVLAARI™ (givosiran) a drug approved by the FDA in November 2019 for the treatment of AHP.

John Temperato, CEO of RDD Pharma and what will be 9 Meters Biopharma, discusses GI diseases, current treatments, why there are still unmet needs for diseases like celiac and others, and what’s on the horizon.  Through the RDD/Innovate merger, 9 Meters will have larazotide, the first-ever drug candidate to enter Phase 3 registration trials for celiac disease.

Dr. Andrew Pecora, CEO of Outcomes Matter Innovations (OMI), a company looking to improve patient results by increasing the value of each doctor’s visit,  discusses the problems and offers solutions, such as changing the payment model and taking administrative work off physicians. 

Dr. Russell Basser, MD, Chief Scientist and Senior VP of Research and Development at Seqirus, discusses the FDA approval of Seqirus’s AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted). This is the first-ever adjuvanted, cell-based pandemic influenza vaccine to protect against influenza A (H5N1) – a subtype of influenza that the U.S. Centers for Disease Control and Prevention says has strong pandemic potential.

Dr. Janet Kennedy, a clinical psychologist, sleep specialist and author of “The Good Sleeper ” and Mary van Praag, President of the Intimates Group of Chico’s FAS, discuss tips for establishing a nighttime routine and share insights on rest from Soma’s national sleep study.

Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041.  The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.

Martin Burns, CEO of BBI (Bruin Biometrics), discusses preventing pressure injuries, the recently updated guidelines by the National Pressure Injury (formerly Ulcer) Advisory Panel, and the financial impact of pressure injuries and how the system can incorporate major change.  After crunching the numbers, analyzing the data and developing technology to create a solution, he believes that true prevention of pressure injuries can finally be made real.  

Dr. Jeff Sharman of Willamette Valley Cancer Institute and Research Center and Nichole Fisher, RN, BSN, discuss recent research presented at the 2019 American Society of Hematology (ASH) Annual Meeting, the current treatment landscape for CLL, and the impact a diagnosis can have on a patient and their loved ones.